This is what the news should sound like. The biggest stories of our time, told by the best journalists in the world. Hosted by Michael Barbaro. Twenty minutes a day, five days a week, ready by 6 a.m. Unlock full access to New York Times podcasts and explore everything from politics to pop culture. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. Listen to this podcast in New York Times Audio, our new iOS app for news subscribers. Download now at nytimes.com/audioapp
…
continue reading
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
S6 Ep11: Biosimilars Immunology Roundup for May 2023—Podcast Edition
MP3•Episode home
Manage episode 365143659 series 2161808
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Show Notes
FDA Approves Celltrion’s Yuflyma, the Ninth Adalimumab Biosimilar
Celltrion Launches Biobetter in Brazil, Shares Phase 3 Plan for MS Biosimilar
Amgen’s Stelara Biosimilar Delayed Until 2025 After Settling With J&J
Dr Colby Evans: The Managed Care Perspective on Biosimilars in Immunology
FDA Approves Celltrion’s Yuflyma, the Ninth Adalimumab Biosimilar
Celltrion Launches Biobetter in Brazil, Shares Phase 3 Plan for MS Biosimilar
Amgen’s Stelara Biosimilar Delayed Until 2025 After Settling With J&J
Dr Colby Evans: The Managed Care Perspective on Biosimilars in Immunology
Dr Vibeke Strand: The Current State of Immunology Biosimilars and the Promise of Future Savings
Samsung Bioepis Report Correlates Biosimilar Pricing Changes With Market Adoption
Biosimilars Business News Recap: A New Partnership; Celltrion Wins Tenders
Tocilizumab Biosimilar LZM008 Demonstrates PK Equivalence in Healthy Participants
RWE: Rituximab Biosimilar GP2013 Effective in Patients With RA After Switching From Originator
155 episodes
MP3•Episode home
Manage episode 365143659 series 2161808
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Show Notes
FDA Approves Celltrion’s Yuflyma, the Ninth Adalimumab Biosimilar
Celltrion Launches Biobetter in Brazil, Shares Phase 3 Plan for MS Biosimilar
Amgen’s Stelara Biosimilar Delayed Until 2025 After Settling With J&J
Dr Colby Evans: The Managed Care Perspective on Biosimilars in Immunology
FDA Approves Celltrion’s Yuflyma, the Ninth Adalimumab Biosimilar
Celltrion Launches Biobetter in Brazil, Shares Phase 3 Plan for MS Biosimilar
Amgen’s Stelara Biosimilar Delayed Until 2025 After Settling With J&J
Dr Colby Evans: The Managed Care Perspective on Biosimilars in Immunology
Dr Vibeke Strand: The Current State of Immunology Biosimilars and the Promise of Future Savings
Samsung Bioepis Report Correlates Biosimilar Pricing Changes With Market Adoption
Biosimilars Business News Recap: A New Partnership; Celltrion Wins Tenders
Tocilizumab Biosimilar LZM008 Demonstrates PK Equivalence in Healthy Participants
RWE: Rituximab Biosimilar GP2013 Effective in Patients With RA After Switching From Originator
155 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.